[Skip to Content]
[Skip to Content Landing]
Views 2,252
Citations 0
Biotech Innovations
December 12, 2017

First Phase 1 Trial of a Prophylactic mRNA Vaccine Reported

JAMA. 2017;318(22):2173. doi:10.1001/jama.2017.19065

Results from the first phase 1 clinical trial investigating a preventive messenger RNA (mRNA) vaccine are in and the outlook for this alternative to inactivated vaccines is promising.

In the proof-of-concept nonrandomized rabies vaccine trial funded by German pharmaceutical company CureVac, mRNA vaccination with a needle-free injection device induced immunogenicity in 32 (71%) of 45 participants given doses intradermally and 6 (45%) of 13 participants given doses intramuscularly. Adverse effects were mostly mild or moderate, with a safety profile similar to inactivated vaccines, said study investigator Frank V. Sonnenburg, MD, a professor in the department of infectious diseases and tropical medicine at the University of Munich. One serious adverse reaction possibly related to the vaccination, a case of Bell palsy, resolved on its own.